康宁杰瑞制药(09966.HK)发布药物KN046之最新临床数据
康宁杰瑞制药(09966.HK)公布,有关KN046(一种重组人源化PD-L1/CTLA-4双特异性抗体)治疗晚期NSCLC患者的II期临床研究的临床数据及KN046治疗罕见胸部肿瘤患者的I期临床研究的初步安全性及疗效结果的摘要已获准於即将举行的2020年世界肺癌大会(WCLC 2020)上展示。
KN046治疗晚期NSCLC患者的II期临床研究的临床数据显示,其具有良好的耐受性,用於晚期NSCLC的二线治疗有效,在NSCLC中显示出PFS及OS获益。而KN046治疗罕见胸部肿瘤患者上具有良好的安全性,并与其他免疫检查点抑制剂一致。KN046已初步显示出良好疗效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.